期刊文献+

坎地沙坦酯的合成工艺改进 被引量:3

Synthesis of candesartan cilexetil
原文传递
导出
摘要 目的研究坎地沙坦酯的合成新方法,并对其工艺路线进行优化。方法以3-硝基邻苯二甲酸为原料,经过酯化、氯化、Curtius重排、脱Boc保护、还原、环合、水解、酯化、烃化、脱保护10步反应得到坎地沙坦酯。结果与结论该路线反应条件温和,原料廉价易得,同时避免了剧毒化合物烷基锡的使用,成本较低,总收率12.3%,适合工业化生产。 Candesartan cilexetil,as new non-peptide angiotensin Ⅱ receptor antagonist,was used for antihypertensive,with the characterstics of long-lasting(1 time/day),good tolerance and high receptor selectivity.It was developed by TAKEDA company and listed in Sweden in 1997 at first.The synthetic routes,taking 3-nitrophthalic acid as staring material,candesartan cilexetil was obtained successfully via ten-step routes of esterification,chlorination,Curtius rearrangement et al with overall yield of 12.3% much higher than that of reported routes.The structure of candesartan cilexetil was confirmed by 1H-NMR,13C-NMR,HRMS,HPLC.
出处 《中国药物化学杂志》 CAS CSCD 2012年第4期290-293,共4页 Chinese Journal of Medicinal Chemistry
关键词 坎地沙坦酯 联苯四氮唑 合成工艺 抗高血压药 candesartan cilexetil biphenyl tetrazoles synthetic process antihypertensive drug
  • 相关文献

参考文献8

  • 1青岛黄海制药有限责任公司.一种制备坎地沙坦酯的方法:中国,101781286A[P].2010-07-21.
  • 2MANOLIS A J, GROSSMAN E, JELAKOVIC B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension [J]. Clin Ther,2000,22(10) :1186 -1203.
  • 3MALMQVIST K, KAHAN T, DAHL M. Angiotensin Ⅱ type 1 ( AT1 ) receptor blockade in hypertensive women:benefits of candesartan cilexetil versus enalapril orhydrochlorothiazide[J]. Am J Hypertens ,2000, 13(5) :504 -511.
  • 4VENKATARAMAN S, REDDY P P,REDDY G S, et al. Process for preparing candesartan cilexetil: WO, 2006/015134[P]. 2006 -02 -09.
  • 5朱琦峰,李海泓,刘光明.抗高血压药坎地沙坦酯的新合成方法[J].中国药物化学杂志,2009,19(3):185-187. 被引量:4
  • 6曹日晖,钟庆华,彭文烈,徐安龙.坎地沙坦酯的合成[J].中国医药工业杂志,2003,34(9):425-427. 被引量:5
  • 7朱彦民,景士云,王钝,吴秀静,宫平.坎地沙坦西来替昔酯的合成工艺改进[J].中国药物化学杂志,2003,13(1):31-33. 被引量:4
  • 8WANG G X, SUN B P, RU Z L. Synthesis and characterization of 4'-bromomethyl-2-( N-trityl-1H-tetrazol-5-yl) biphenyl [J]. Synth Commun, 2008,38 (20) :3577 - 3581.

二级参考文献15

  • 1何颖娜,尚京川.抗高血压新药——坎地沙坦酯[J].重庆医学,2004,33(12):1896-1898. 被引量:14
  • 2邢为凡,韩冬梅,陈淑珍,邢亚菲.头孢泊肟酯合成研究Ⅰ.1-碘乙基异丙基碳酸酯的制备[J].中国药科大学学报,1996,27(4):198-201. 被引量:9
  • 3KUBO K,KOHARA Y,IMAMIYA E,et al. Nonpeptide angiotensin Ⅱ receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids [J]. J Med Chem,1993,36(15) :2182 -2195.
  • 4Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use : EP, 0459136 [ P ]. 1991 - 12 - 04.
  • 5Takeda Chemical Industries, Ltd. Production method of aminobenzene compound: EP, 881212 [ P ]. 1998 - 12 - 02.
  • 6中国科学院上海药物研究所.坎地沙坦酯的合成新路线:中国.1361101AfPt.2002-07-31.
  • 7KOBE T N, KYOTO K N, HIGASHJOSAKA T K, et al. 1-(Cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1- { [ 2'-( 1H-tetrazol-5-yl ) biphenyl-4-yl ] methyl } -1H- benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof: US, 5196444 [P]. 1993 -05 -23.
  • 8Kobe TN, Kyoto KN, Higashiosaka TK, et al. 1-( Cyclohexyloxycarbonyloxy ) ethyl 2-ethoxy-1- { [ 2'-( 1H-tetrazol-5-yl ) biphenyl-4-yl ] methyl }-lH-benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof[P]. US: 5196444,1993-05-23. (CA 1993,116:128924).
  • 9Manolis A J, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension[J]. Clin Ther,2000,22(10) :1186-1203.
  • 10Malmqvist K, Kahan T, Dahl M. Angiotensin I type 1 (AT1) receptor blockade in hypertensive women :benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide[J]. Am J Hypertens, 2000,13 ( 5 ) :504-511.

共引文献8

同被引文献27

  • 1苏国强,郭涤亮,朱兰,朱崇泉.坎地沙坦的合成方法研究[J].中国药科大学学报,2005,36(2):190-192. 被引量:8
  • 2White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilasartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension E J3. Hypertension, 2011, 57 (3): 413-420.
  • 3Kohara Y, Imamiya E, Kubo K, et al. A new class of angiotensin II receptor antagonists with a novel acidic bioisostere EJl. Bioorg Med Chem Lett, 1995, 5(17): 1903-1908.
  • 4Porcs-makkay M, MEzei T, Simig G. New practical synthesis of the key intermediate of candesartan [J]. Org Process Res Dev, 2007, 11 (3) : 490-493.
  • 5Srinivas V, Reddy GS, Reddy PP, et al. Process for preparing candesartan cilexetil: WO, 2006015134 [P]. 2006-02-09.
  • 6Kubo K, Kohara Y, Imamiya E, et al. Nonpeptide angiotensin II receptor antagonists synthesis and biological activity of benzimidazolecarboxylic acids [J]. J Med Chem, 1993, 36 (15) : 2182-2195.
  • 7Kohei N, Naka T, Kato T. 1-(cyclohexyloxycarbonyloxy)- ethyl 2-ethoxy- 1- [ [2'- (1H-tetrazol-5-yl) biphenyl-4-yl] - methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof: US, 5196444 [P]. 1993-05-25. (CA 1993, 116: 128924).
  • 8Inada Y, Naka T. Compound which is angiotensin II antagonist: US, 5243054 [P]. 1993-09-07.
  • 9陈林.一种阿齐沙坦的制备方法:中国,102766138[P].2012.11-07.
  • 10Kohara Y, Kubo K, Imamiya E, et al. Synthesis and angiotensin II receptor antagonistic activities ofbenzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres [J]. JMed Chem, 1996, 39(26) : 5228-5235.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部